KR20140036257A - 다발성 경화증 치료 및 미엘린 함량 보존 및/또는 증가 방법 - Google Patents

다발성 경화증 치료 및 미엘린 함량 보존 및/또는 증가 방법 Download PDF

Info

Publication number
KR20140036257A
KR20140036257A KR1020137034196A KR20137034196A KR20140036257A KR 20140036257 A KR20140036257 A KR 20140036257A KR 1020137034196 A KR1020137034196 A KR 1020137034196A KR 20137034196 A KR20137034196 A KR 20137034196A KR 20140036257 A KR20140036257 A KR 20140036257A
Authority
KR
South Korea
Prior art keywords
subject
fumarate
reduced
years
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020137034196A
Other languages
English (en)
Korean (ko)
Inventor
캐서린 도슨
길모어 오닐
알프레드 샌드록
Original Assignee
바이오겐 아이덱 엠에이 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47217796&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20140036257(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 바이오겐 아이덱 엠에이 인코포레이티드 filed Critical 바이오겐 아이덱 엠에이 인코포레이티드
Publication of KR20140036257A publication Critical patent/KR20140036257A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020137034196A 2011-05-26 2012-05-25 다발성 경화증 치료 및 미엘린 함량 보존 및/또는 증가 방법 Withdrawn KR20140036257A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161490572P 2011-05-26 2011-05-26
US61/490,572 2011-05-26
US201261625624P 2012-04-17 2012-04-17
US61/625,624 2012-04-17
PCT/US2012/039721 WO2012162669A1 (en) 2011-05-26 2012-05-25 Methods of treating multiple sclerosis and preserving and/or increasing myelin content

Publications (1)

Publication Number Publication Date
KR20140036257A true KR20140036257A (ko) 2014-03-25

Family

ID=47217796

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137034196A Withdrawn KR20140036257A (ko) 2011-05-26 2012-05-25 다발성 경화증 치료 및 미엘린 함량 보존 및/또는 증가 방법

Country Status (19)

Country Link
US (1) US20140163100A1 (cg-RX-API-DMAC7.html)
EP (1) EP2713724A4 (cg-RX-API-DMAC7.html)
JP (1) JP2014515373A (cg-RX-API-DMAC7.html)
KR (1) KR20140036257A (cg-RX-API-DMAC7.html)
CN (1) CN103732062A (cg-RX-API-DMAC7.html)
AU (1) AU2012258558A1 (cg-RX-API-DMAC7.html)
BR (1) BR112013030169A2 (cg-RX-API-DMAC7.html)
CA (1) CA2836480A1 (cg-RX-API-DMAC7.html)
CL (1) CL2013003358A1 (cg-RX-API-DMAC7.html)
CO (1) CO6811862A2 (cg-RX-API-DMAC7.html)
EA (1) EA201391578A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP13013117A (cg-RX-API-DMAC7.html)
IL (1) IL229448A0 (cg-RX-API-DMAC7.html)
MX (1) MX2013013781A (cg-RX-API-DMAC7.html)
PE (1) PE20141316A1 (cg-RX-API-DMAC7.html)
PH (1) PH12013502443A1 (cg-RX-API-DMAC7.html)
SG (1) SG195049A1 (cg-RX-API-DMAC7.html)
WO (1) WO2012162669A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201308681B (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1663197T3 (da) 2003-09-09 2008-01-07 Fumapharm Ag Anvendelse af fumarsyrederivater til behandling af hjerteinsuffiens og astma
SI1799196T1 (sl) 2004-10-08 2016-10-28 Forward Pharma A/S Farmacevtski sestavki z nadzorovanim sproščanjem, obsegajoči ester fumarne kisline
MX2011001341A (es) 2008-08-19 2011-03-29 Xenoport Inc Prodrogas de metil hidrogeno fumarato, sus composiciones farmaceuticas, y metodos de uso.
PE20141639A1 (es) 2011-06-08 2014-11-08 Biogen Idec Inc Proceso para preparar fumarato de dimetilo de alta pureza y cristalino
EP2887934A1 (en) 2012-08-22 2015-07-01 XenoPort, Inc. Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
US20140057918A1 (en) * 2012-08-22 2014-02-27 Xenoport, Inc. Methods of Use for Monomethyl Fumarate and Prodrugs Thereof
US9597292B2 (en) 2012-08-22 2017-03-21 Xenoport, Inc. Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof
AR094277A1 (es) 2012-12-21 2015-07-22 Biogen Idec Inc Derivados de fumarato sustituidos con deuterio
MX386935B (es) 2013-03-14 2025-03-04 Alkermes Pharma Ireland Ltd Profármacos de fumaratos y su uso en el tratamiento de diferentes enfermedades.
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
US10179118B2 (en) 2013-03-24 2019-01-15 Arbor Pharmaceuticals, Llc Pharmaceutical compositions of dimethyl fumarate
WO2014197860A1 (en) 2013-06-07 2014-12-11 Xenoport, Inc. Method of making monomethyl fumarate
US9421182B2 (en) 2013-06-21 2016-08-23 Xenoport, Inc. Cocrystals of dimethyl fumarate
JP2016534133A (ja) 2013-09-06 2016-11-04 ゼノポート,インコーポレイティド (n,n−ジエチルカルバモイル)メチル メチル(2e)ブト−2−エン−1,4−ジオエートの結晶形態、その合成方法及び使用
CN103724198A (zh) * 2013-11-28 2014-04-16 镇江圣安医药有限公司 富马酸二甲酯的新型衍生物及其应用
JP6337135B2 (ja) 2014-02-24 2018-06-06 アルカーメス ファーマ アイルランド リミテッド フマル酸エステルのスルホンアミドプロドラッグ及びスルフィンアミドプロドラッグ並びに種々の疾患の治療におけるその使用
CA2939990C (en) 2014-02-28 2018-07-10 Banner Life Sciences Llc Controlled release enteric soft capsules of fumarate esters
US10098863B2 (en) 2014-02-28 2018-10-16 Banner Life Sciences Llc Fumarate esters
US9326947B1 (en) 2014-02-28 2016-05-03 Banner Life Sciences Llc Controlled release fumarate esters
US9636318B2 (en) 2015-08-31 2017-05-02 Banner Life Sciences Llc Fumarate ester dosage forms
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
CA2965449C (en) * 2014-10-27 2020-11-10 Cellix Bio Private Limited Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
MA40985A (fr) * 2014-11-17 2017-09-26 Biogen Ma Inc Méthodes de traitement de la sclérose en plaques
MA41139B1 (fr) * 2014-12-11 2026-02-27 Laboratoires Juvise Pharmaceuticals Combinaison pharmaceutique comprenant du ponesimod et son utilisation dans le traitement de la sclérose en plaque
HUE057865T2 (hu) 2014-12-11 2022-06-28 Actelion Pharmaceuticals Ltd A poneszimodra, egy szelektív S1P1 receptor agonistára vonatkozó adagolási rend
GB201907882D0 (en) 2019-06-03 2019-07-17 Cyprus Foundation For Muscular Dystrophy Res Methods
WO2021142062A1 (en) 2020-01-10 2021-07-15 Banner Life Sciences Llc Fumarate ester dosage forms with enhanced gastrointestinal tolerability

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19721099C2 (de) * 1997-05-20 1999-12-02 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten
DE19853487A1 (de) * 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
CA2478458A1 (en) * 2004-08-20 2006-02-20 Michael Panzara Treatment of pediatric multiple sclerosis
CN101056624A (zh) * 2004-10-08 2007-10-17 Adi技术制药股份公司 包含富马酸酯的控释药物组合物
WO2007042034A1 (en) * 2005-10-07 2007-04-19 Aditech Pharma Ab Controlled release pharmaceutical compositions comprising a fumaric acid ester
HUE032251T2 (en) * 2007-02-08 2017-09-28 Biogen Ma Inc Neuroprotection in demyelinating diseases
EP2653873B8 (en) * 2007-02-08 2022-08-24 Biogen MA Inc. Compositions and uses for treating Multiple Sclerosis
MX2011001341A (es) * 2008-08-19 2011-03-29 Xenoport Inc Prodrogas de metil hidrogeno fumarato, sus composiciones farmaceuticas, y metodos de uso.
EP3318249A1 (en) * 2009-04-29 2018-05-09 Biogen MA Inc. Dimethyl fumarate dosage regimens for the treatment of multiple sclerosis

Also Published As

Publication number Publication date
PE20141316A1 (es) 2014-10-01
ECSP13013117A (es) 2014-06-30
WO2012162669A1 (en) 2012-11-29
MX2013013781A (es) 2014-01-08
CN103732062A (zh) 2014-04-16
JP2014515373A (ja) 2014-06-30
EP2713724A4 (en) 2015-03-11
IL229448A0 (en) 2014-01-30
ZA201308681B (en) 2017-11-29
EP2713724A1 (en) 2014-04-09
AU2012258558A1 (en) 2013-05-02
PH12013502443A1 (en) 2019-03-22
BR112013030169A2 (pt) 2016-08-09
CA2836480A1 (en) 2012-11-29
SG195049A1 (en) 2013-12-30
CO6811862A2 (es) 2013-12-16
US20140163100A1 (en) 2014-06-12
EA201391578A1 (ru) 2014-05-30
CL2013003358A1 (es) 2014-08-01

Similar Documents

Publication Publication Date Title
US20140163100A1 (en) Methods of Treating Multiple Sclerosis and Preserving and/or Increasing Myelin Content
EP1001760B1 (en) Composition for controlling mood disorders in healthy individuals
US20210030665A1 (en) Synthetic transdermal cannabidiol for the treatment of focal epilepsy in adults
ES2952727T3 (es) Tratamiento de la enfermedad de Alzheimer en una población de pacientes particular
JP6837486B2 (ja) 加齢に関連する認知障害及び神経炎症を予防及び/又は治療する方法
RS51961B (sr) Primena flibanserina za lečenje poremećaja seksualne želje u premenopauzi
EP3843723B1 (en) Composition for eradicating helicobacter pylori
US20200323817A1 (en) Methods and compositions for treatment of alzheimer's disease and other neurodegenerative disorders
US20170312265A1 (en) Method for improving interstitial flow
JP2024133735A (ja) Iv型コラーゲン疾患の処置のためのビフェニルスルホンアミド化合物
CN117295501A (zh) 治疗食管狭窄的方法
CN120899718A (zh) 用于治疗路易体痴呆的组合物和方法
EA001325B1 (ru) Способы лечения и профилактики интерстициального цистита
KR100692235B1 (ko) 안지오텐신 ⅱ 길항물질의 신규한 용도
SE1350211A1 (sv) Metoder och kompositioner för behandling av cancermetastaser
Stansley et al. The small molecule simufilam dose‐dependently attenuates the worsening of seizures in a mouse model of tuberous sclerosis complex
CN1135180A (zh) 盘昔洛维治疗带状疱疹后神经痛的应用
US20150037399A1 (en) Novel use of pipoxolan and its pharmaceutical composition
HUP0302371A2 (hu) Béta-blokkolót és adott esetben koleszterinszint-csökkentőt tartalmazó új gyógyszerkészítmény
WO2025085050A1 (en) Treatment of frontal fibrosing alopecia
JP5707137B2 (ja) レバミピドの骨粗鬆症治療用途
HK40094581A (en) Treatment of alzheimer's disease in a particular patient population
AU2024359133A1 (en) Combination of a parp-1 selective inhibitor and temozolimde and its use in the treatment of glioma
HK40059411B (en) Biphenyl sulfonamide compounds for the treatment of type iv collagen diseases
HK40059411A (en) Biphenyl sulfonamide compounds for the treatment of type iv collagen diseases

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20131223

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid